munchtrade wrote: ChuckFoo wrote: munchtrade wrote: The fact that the pending patent continues to be hidden kind of worries me
More than the fact that a single product using the tech hasn't hit the shelves? I wouldn't care who else is trying to copy the tech if it meant it actually works and is Health Canada approved. That is the catalyst. The fact that A88 walked away is worrisome, despite what Sen may have said to a random anonymous guy who apparently phoned him out of the blue somehow.
I didn't say it was my ONLY worry :)
For me, investing in the SPR story takes a certain level of faith that the information provided and publicly available is true. That assumption probably is valid for investing in any company, but especially so for a micro-startup in a non-existent industry.
My analysis (and gut) tells me the tech is valid based on the Moosehead arrangement. Moose validate the tech. On face-value, the reason for the delays in finalizing the JV is the co-packer agreement, which was cited as a primary reason for delay. I haven't detected any attempts at deception from SPR on anything, so I continue to buy the story, and that point that keeps me from getting too concerned about the tech.
On the A88 stuff - hard to say really what drove that decision - one other conceivable reason is that A88 is looking at CBD only beverages, where fast onset/offset isn't necessarily a primary drving force, so maybe they did a cost review and went a different direction. Just more speculation.
Why don't you care about patent protection? The way I see it, that's huge upside that gets cut down if it can't be enforced.